文献速递炎症性肠病

STRIDE-II:IOIBD关于炎症性肠病治疗目标选择的更新

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
PubMed 文献 · Gastroenterology · 2021-02-19

IOIBD基于系统综述与89名成员两轮调查投票更新STRIDE共识,共筛选11278篇文献纳入435篇,最终13条推荐获认可。STRIDE-II确认临床缓解与内镜愈合为长期目标,新增无残疾、生活质量恢复及儿童正常生长,症状缓解与血清/粪便标志物正常化为短期目标。

要点

  • 长期目标:临床缓解、内镜愈合、无残疾、生活质量恢复、儿童正常生长。
  • 短期目标:症状缓解及CRP/ESR和钙卫蛋白正常化。
  • 克罗恩病透壁愈合与溃疡性结肠炎组织学愈合非正式目标但应评估。

核心结论

  • STRIDE-II提供基于证据与共识的成人和儿童IBD达标治疗推荐框架。
  • 该框架应结合个体患者与当地资源调整以改善结局。

研究设计与样本

  • 基于系统综述与对89名IOIBD成员的两轮调查和两轮投票制定推荐。
  • 共识定义为至少75%参与者在10分制评分中给出7至10分。
  • 系统综述筛选11278篇稿件,最终纳入435篇。

主要发现

  • 首次调查确定最重要的目标为临床应答与缓解、内镜愈合及CRP/ESR和钙卫蛋白正常化。
  • 共识别15条推荐,其中13条获认可。
  • STRIDE-II确认STRIDE-I的长期目标临床缓解与内镜愈合,并新增无残疾、生活质量恢复和儿童正常生长。
  • 症状缓解与血清及粪便标志物正常化被确定为短期目标。
  • 克罗恩病透壁愈合与溃疡性结肠炎组织学愈合非正式目标,但应作为缓解深度指标评估。

关键数值与推荐

  • 共识阈值:至少75%参与者在10分制评分中给出7至10分。
  • 长期目标:临床缓解、内镜愈合、无残疾、生活质量恢复、儿童正常生长。
  • 短期目标:症状缓解及CRP/ESR和钙卫蛋白正常化。

临床怎么用

  • 成人及儿童IBD达标治疗应采用STRIDE-II框架设定短期与长期目标。
  • 克罗恩病可评估透壁愈合、溃疡性结肠炎可评估组织学愈合以判断缓解深度。
  • 框架需结合个体患者与当地资源进行适应性调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) has proposed treatment targets in 2015 for adult patients with inflammatory bowel disease (IBD). We aimed to update the original STRIDE statements for incorporating treatment targets in both adult and pediatric IBD. METHODS: Based on a systematic review of the literature and iterative surveys of 89 IOIBD members, recommendations were drafted and modified in 2 surveys and 2 voting rounds. Consensus was reached if ≥75% of participants scored the recommendation as 7 to 10 on a 10-point rating scale. RESULTS: In the systematic review, 11,278 manuscripts were screened, of which 435 were included. The first IOIBD survey identified the following targets as most important: clinical response and remission, endoscopic healing, and normalization of C-reactive protein/erythrocyte sedimentation rate and calprotectin. Fifteen recommendations were identified, of which 13 were endorsed. STRIDE-II confirmed STRIDE-I long-term targets of clinical remission and endoscopic healing and added absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers have been determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth. CONCLUSIONS: STRIDE-II encompasses evidence- and consensus-based recommendations for treat-to-target strategies in adults and children with IBD. This frameworkshould be adapted to individual patients and local resources to improve outcomes.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021. PMID: 33359090. doi:10.1053/j.gastro.2020.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。